KALA

KALA BIO, Inc.

0.58 USD

Last updated Sep 12, 02:43 UTC

Yesterday HIGH

$0.6

Yesterday LOW

$0.55

52w HIGH

$1,029

52w LOW

$0.49

EPS

-21.32

PE

-0.03

Next Earnings

Nov 18, 2026

Overview News Government Trades Fundamentals

KALA BIO, Inc. stock is down -36.62% since 30 days ago. The next earnings date is Nov 18, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 9 September’s closed higher than August.

Benzinga Newsdesk

Wed Aug 19, 2026

Kala Bio Q2 EPS $(21.32) Up From $(85.64) YoY, Sales $0.00, Same YoY

Kala Bio (NASDAQ:KALA) reported quarterly losses of $(21.32) per share. This is a 75.11 percent increase over losses of $(85.64) per share from the same period last year. The company reported $0.00 in sales this
Benzinga Newsdesk

Wed Jul 22, 2026

Kala Bio Files ATM Offering Of Up To $250M In Common Stock

-SEC Filing
Benzinga Newsdesk

Fri May 15, 2026

Kala Bio Q1 EPS $(0.14) Beats $(0.30) Estimate

Kala Bio (NASDAQ:KALA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.30) by 53.33 percent. This is a 99.8 percent increase over losses of $(70.49) per share from the same
Benzinga Newsdesk

Mon May 11, 2026

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Benzinga Newsdesk

Thu May 7, 2026

KALA BIO shares are trading lower after the company announced a 1-for-50 reverse stock split.
Benzinga Newsdesk

Thu May 7, 2026

Kala Bio Announces 1-For-50 Reverse Stock Split, Effective May 11

KALA BIO, Inc. (NASDAQ: KALA) ("KALA BIO" or the "Company"), today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the "common stock") at a ratio of 1 post-split
Benzinga Insights

Mon Apr 27, 2026

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Newsdesk

Wed Apr 15, 2026

Kala Bio Q4 EPS $0.86 Beats $(1.44) Estimate, Sales $0.00

Kala Bio (NASDAQ:KALA) reported quarterly earnings of $0.86 per share which beat the analyst consensus estimate of $(1.44) by 159.72 percent. This is a 149.43 percent increase over losses of $(1.74) per share from the
Avi Kapoor

Wed Apr 8, 2026

Top 3 Health Care Stocks Which Could Blast Off This Quarter

Undervalued companies in health care sector with low RSI values present buying opportunity: PepGen Inc (PEPG), KALA BIO Inc (KALA), Viridian Therapeutics Inc (VRDN)
Benzinga Insights

Wed Apr 1, 2026

12 Health Care Stocks Moving In Wednesday's Pre-Market Session